A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets for breast cancer
- PMID: 38834774
- DOI: 10.1007/s10549-024-07373-z
A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets for breast cancer
Abstract
Background: Adhesion G protein-coupled receptors (aGPCRs), a distinctive subset of the G protein-coupled receptor (GPCR) superfamily, play crucial roles in various physiological and pathological processes, with implications in tumor development. Despite the global prevalence of breast cancer (BRCA), specific aGPCRs as potential drug targets or biomarkers remain underexplored.
Methods: UALCAN, GEPIA, Kaplan-Meier Plotter, MethSurv, cBiopportal, String, GeneMANIA, DAVID, Timer, Metascape, and qPCR were applied in this work.
Results: Our analysis revealed significantly increased transcriptional levels of ADGRB2, ADGRC1, ADGRC2, ADGRC3, ADGRE1, ADGRF2, ADGRF4, and ADGRL1 in BRCA primary tumors. Further analysis indicated a significant correlation between the expressions of certain aGPCRs and the pathological stage of BRCA. High expression of ADGRA1, ADGRF2, ADGRF4, ADGRG1, ADGRG2, ADGRG4, ADGRG6, and ADGRG7 was significantly correlated with poor overall survival (OS) in BRCA patients. Additionally, high expression of ADGRF2 and ADGRF4 indicated inferior recurrence-free survival (RFS) in BRCA patients. The RT-qPCR experiments also confirmed that the mRNA levels of ADGRF2 and ADGRF4 were higher in BRCA cells and tissues. Functional analysis highlighted the diverse roles of aGPCRs, encompassing GPCR signaling and metabolic energy reserves. Moreover, aGPCRs may exert influence or actively participate in the development of BRCA through their impact on immune status.
Conclusion: aGPCRs, particularly ADGRF2 and ADGRF4, hold promise as immunotherapeutic targets and prognostic biomarkers in BRCA.
Keywords: Adhesion GPCRs; BRCA; Bioinformatics analysis; Immunotherapeutic target; Prognostic biomarker.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets in Uterine Corpus Endometrial cancer.Int Immunopharmacol. 2022 Jul;108:108743. doi: 10.1016/j.intimp.2022.108743. Epub 2022 Apr 9. Int Immunopharmacol. 2022. PMID: 35413679
-
International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors.Pharmacol Rev. 2015;67(2):338-67. doi: 10.1124/pr.114.009647. Pharmacol Rev. 2015. PMID: 25713288 Free PMC article. Review.
-
High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer.BMC Cancer. 2021 Dec 7;21(1):1305. doi: 10.1186/s12885-021-09010-0. BMC Cancer. 2021. PMID: 34876062 Free PMC article.
-
NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.Clin Epigenetics. 2021 May 17;13(1):112. doi: 10.1186/s13148-021-01096-4. Clin Epigenetics. 2021. PMID: 34001208 Free PMC article.
-
Role of ADGRG1/GPR56 in Tumor Progression.Cells. 2021 Nov 29;10(12):3352. doi: 10.3390/cells10123352. Cells. 2021. PMID: 34943858 Free PMC article. Review.
Cited by
-
Synthesis and Biological Evaluation of Herceptin-Conjugated Liposomes Loaded with Lipocalin-2 siRNA for the Treatment of Inflammatory Breast Cancer.Pharmaceuticals (Basel). 2025 Jul 17;18(7):1053. doi: 10.3390/ph18071053. Pharmaceuticals (Basel). 2025. PMID: 40732340 Free PMC article.
-
The Use of Biologics for Targeting GPCRs in Metastatic Cancers.BioTech (Basel). 2025 Jan 30;14(1):7. doi: 10.3390/biotech14010007. BioTech (Basel). 2025. PMID: 39982274 Free PMC article. Review.
-
The atypical adhesion GPCR ADGRA1 controls hippocampal inhibitory circuit function.bioRxiv [Preprint]. 2025 Jul 30:2025.07.30.667713. doi: 10.1101/2025.07.30.667713. bioRxiv. 2025. PMID: 40766348 Free PMC article. Preprint.
-
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy.J Immunother Cancer. 2025 Apr 23;13(4):e011379. doi: 10.1136/jitc-2024-011379. J Immunother Cancer. 2025. PMID: 40274284 Free PMC article.
References
-
- Gurevich VV, Gurevich EV (2019) Gpcr signaling regulation: the role of GRKs and Arrestins. Front Pharmacol 10:437285 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous